SCHEMBL17186356

SCHEMBL17186356

Nc1nc2[nH]cnc2c(=O)n1Cc1ccc(F)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 1/20 0.39
▸ SOS1 Q07889 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.38
▸ TRAP1 Q12931 2/20 0.37
▸ P2RX7 Q99572 2/20 0.37
▸ CSF1R P07333 1/20 0.36
▸ MPO P05164 1/20 0.36
▸ TPO P07202 1/20 0.36
▸ GPR18 Q14330 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ PDPK1 O15530 2/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17186369 0.99 PNP (0.39) PNPSOS1TLR7TRAP1P2RX7
SCHEMBL17186469 0.90 SOS1 (0.39) PNPSOS1P2RX7CSF1RMPO
SCHEMBL17186560 0.90 PNP (0.37) PNPSOS1TRAP1P2RX7MPO
Hydrochloric Acid SCHEMBL17186243 0.89 SOS1 (0.39) PNPSOS1P2RX7CSF1RMPO
Hydrochloric Acid SCHEMBL17186507 0.89 PNP (0.37) PNPSOS1TRAP1P2RX7MPO
SCHEMBL17186281 0.88 DAO (0.39) PNPTLR7MPOGPR18USP2
Hydrochloric Acid SCHEMBL17186586 0.87 DAO (0.39) PNPTLR7MPOGPR18USP2
SCHEMBL1533545 0.86 MPO (0.48) PNPP2RX7MPOTPOPDE4A
SCHEMBL3308556 0.85 PNP (0.45) PNPSOS1TLR7PDE4APDE4B
SCHEMBL9234445 0.85 PNP (0.44) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US claimed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP claimed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO claimed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 — — EP disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US disclosed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 PNP 292/4885SOS1 4702/4885TLR7 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback